WEDNESDAY, July 16, 2025 (HealthDay News) — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets […]
The post Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma first appeared on Blackandmed .
